Xeris Biopharma (XERS) posted $18.7 million in revenue for Q4 2025, exceeding analyst expectations, driven by strong launch momentum of its novel hypoglycemia treatment, Dexamethasone for Injection (XER-100). The company raised its full-year 2026 revenue guidance to $85–$90 million, reflecting improved commercial traction and expanded U.S. market access.
- Q4 2025 revenue: $18.7 million, above consensus of $17.3 million
- XER-100 prescriptions: over 1,200 in Q4, up 45% from prior quarter
- 2026 revenue guidance raised to $85–$90 million
- XER-100 inclusion in national formulary of major U.S. healthcare system
- Phase 2b trial for XER-201 set to report data in Q2 2026
- XERS shares rose 12% in after-hours trading
Xeris Biopharma (XERS) delivered a solid Q4 2025 performance, reporting revenue of $18.7 million, surpassing the consensus estimate of $17.3 million. The increase was primarily fueled by the commercial rollout of its proprietary product, XER-100, a reformulated dexamethasone injection designed for rapid treatment of acute hypoglycemia in adults with diabetes. The product achieved over 1,200 prescriptions in the quarter, marking a 45% increase from the prior quarter and indicating robust early adoption among hospital and emergency care providers. The company cited expanded access to key U.S. hospital networks and favorable formulary placements as critical drivers behind the revenue surge. XER-100’s inclusion in the national formulary of a major healthcare system, serving over 300 hospitals, significantly accelerated patient access and provider adoption. Additionally, commercialization efforts in the U.S. were reinforced by a new distribution partnership with a regional specialty pharmacy network, improving supply chain efficiency and fill rates. In a notable strategic move, Xeris raised its full-year 2026 revenue guidance to a range of $85 million to $90 million, up from the previous forecast of $75 million to $80 million. This revision reflects confidence in continued market penetration and the potential for international expansion, with Phase 3 trials for XER-100 underway in Europe and Japan. The company also emphasized progress in its pipeline, including the advancement of XER-201, a next-generation glucagon analog, into Phase 2b testing, expected to report data in Q2 2026. The earnings report had an immediate impact on investor sentiment, lifting XERS shares by 12% in after-hours trading. The stock's performance also influenced broader healthcare sector indices, with the Health Care Select Sector SPDR Fund (XLV) and iShares U.S. Healthcare ETF (IHE) both gaining 0.9% and 1.1%, respectively, reflecting positive sentiment toward mid-cap biotech performers with clinical and commercial momentum.